VANCOUVER, BC / February 1, 2018 / CVR Medical Corp. (TSX.V: CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the launch of their Pre-Pivotal Trial clinical substantiation phase for the “Carotid Stenotic Scan (CSS)” device. This critical stage, prior to launch of final phase Pivotal Trials, will be conducted at Thomas Jefferson University Hospital (Philadelphia, PA), Henry Ford Hospital (Detroit, MI), and several other top-tier clinical research institutions within the United States. Transition from Pre-Pivotal trial phase to Pivotal Trials is expected to occur in the early part of February 2018, and only requires the placement of wireless CSS devices across CVR’s full clinical trial footprint. With the data produced through the Pivotal Trials, CVR will validate the safety and accuracy of their patented device as required for submission to FDA for market clearance.
“Now that we have cleared the major manufacturing and logistical hurdles which all companies encounter when attempting to manufacture a state of the art medical device and arm clinicians across the globe, it is time to start bringing the pre-market phase of this project to a close.” CVR COO Tony Robinson declares with assurance. “The product is designed, the market has told us there is a need, and we have laid the path to manufacture the CSS, now it is time to execute. We intend for this last clinical phase to be swift and efficient, a closing to this chapter of development.”
CVR Medical plans to announce the additional Pivotal Trial locations immediately upon IRB approval.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888